The most frequently mutated tumor suppressor gene in cancer, TP53, showed a higher mutation prevalence in gastric cancers with high CDX2 expression (54.2% versus 27.4% in cancers with low CDX2, Fisher’s exact test p = 0.0002, Figure 1). This evidence concerns the gene CDX2 and cancer.